Insider Transactions in Q2 2022 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,083
-21.19%
|
$6,166
$2.3 P/Share
|
|
Jun 30
2022
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,913
+37.99%
|
-
|
|
Jun 30
2022
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+22.21%
|
-
|
|
Jun 30
2022
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,999
-11.59%
|
$13,998
$2.3 P/Share
|
|
Jun 30
2022
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,882
+28.34%
|
-
|
|
Jun 30
2022
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+20.61%
|
-
|
|
Jun 30
2022
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+1.28%
|
-
|
|
Jun 30
2022
|
Andrew Cittadine Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,812
-34.61%
|
$5,624
$2.3 P/Share
|
|
Jun 30
2022
|
Andrew Cittadine Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,125
+50.0%
|
-
|
|
Jun 30
2022
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+16.0%
|
-
|